Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes | Zendy

Charlotte Andersson | Zendy; Stig Lyngbæk | Zendy; Cu Dinh Nguyen | Zendy; Mia Nielsen | Zendy; Gunnar Gislason | Zendy; Lars Køber | Zendy; Christian TorpPedersen | Zendy

Open Access

Association of Clopidogrel Treatment With Risk of Mortality and Cardiovascular Events Following Myocardial Infarction in Patients With and Without Diabetes

Author(s) -

Charlotte Andersson,

Stig Lyngbæk,

Cu Dinh Nguyen,

Mia Nielsen,

Gunnar Gislason,

Lars Køber,

Christian TorpPedersen

Publication year - 2012

Publication title -

jama

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 4.688

H-Index - 680

eISSN - 1538-3598

pISSN - 0098-7484

DOI - 10.1001/2012.jama.10779

Subject(s) - medicine , clopidogrel , diabetes mellitus , hazard ratio , myocardial infarction , cardiology , type 2 diabetes , comorbidity , confidence interval , endocrinology

Pharmacodynamic studies have shown that persistently high platelet reactivity is common in patients with diabetes in spite of clopidogrel treatment. Clinical trials have not convincingly demonstrated that clopidogrel benefits patients with diabetes as much patients without diabetes.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research